Emerald Cup Interviews: Brian Applegarth: Head of Travel & Tourism: Sunstone Winery

In this exclusive interview, sponsored by Urbana and brought to you by Highly Capitalized Network, we talk with Brian Applegarth, Head of Travel & Tourism at Sunstone Winery, live from the 20th anniversary of The Emerald Cup 2024. Filmed at the Henry J. Kaiser Center for the Arts in Oakland, California, this landmark event celebrates the intersection of culture and cannabis in the Bay. Gain valuable insights from cannabis leaders, captured right on the floor of The Emerald Cup, where Urbana’s lively booth set the stage for these conversations.

Urbana: Oakland’s Premier Dispensary & Lounge

Urbana is a leading company in California’s cannabis retail sector, renowned for its innovative approach and dedication to excellence. Urbana’s modern, customer-friendly consumption lounges set the standard for on-site consumption, making it a benchmark for the industry. Building on this success, Urbana is set to open a premier location in Oakland this summer. Download Urbana’s Deck and learn more: here.

About the Author: HCN News Team

The News Team at Highly Capitalized are some of the most experienced writers in cannabis and psychedelics business & finance. We cover capital markets, finance, branding, marketing and everything important in between. Most of all, we follow the money.

Share This Story, Choose Your Platform!

Related Posts

HCN NECANN Interviews: Rick Laneve: Founder & CEO of Accounting Buds
High Finance with Peter Su ft. Marc Hauser: Founder: Cannabis Musings
High Finance with Peter Su ft. Kathryn Tucker: Director of Advocacy: National Psychedelics Association
High Finance with Peter Su ft. Frank Colombo: Managing Director: Viridian Capital Advisors
MJBizCon25 Interviews: Seth Yakatan: CEO: Katan Associates International

Latest News

Compass Builds a Commercial Case for COMP360

October 13th, 2026|

NEW YORK – Compass Pathways is advancing COMP360, its proprietary synthetic psilocybin for treatment-resistant depression (TRD), through a rolling FDA New Drug Application, with a commercial launch targeted for H1 2027. Alongside the regulatory push, ...